ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

CPRIT Awards $107.2 Million Round of Grants

September 5, 2014

NCAB Oks LANs To Links NCI Staff With Each Other, The World

February 14, 1992

FDA Announces Plan to Reform Drug Approval, Hire Outside Experts To Handel Some Reviews

November 22, 1991

Sieving Named Director, National Eye Insitute.

January 19, 2001

BCI Budget Chief Browning To Retire

January 12, 1979

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

July 27, 2012